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The primary focus of this research is the mechanisms of cell death in head and 
neck squamous cell carcinoma (HNSCC) treatment. These cancers typically originate in 
squamous cells that line the moist mucosal surfaces of head and neck. HNSCC is 
commonly treated with a platinum based agent, cisplatin. While the drug does offer 
strong antitumor effects, its prolonged use often results in tumor-acquired resistance, 
which limits treatment effectiveness. We have shown that cisplatin treatment induces the 
expression of a pro-apoptotic BCL-2 family member Noxa, which then initiates caspase-
dependent apoptosis through its binding and sequestration of pro-survival protein MCL-1 
for its inactivation. Without Noxa induction, cell death is significantly reduced when 
x	
	
treating HNSCCs with cisplatin. The objectives of this study are (1) to determine the 
molecular mechanisms by which Noxa induces cell death in HNSCC cells; (2) to 
determine the molecular mechanisms of cisplatin-resistance in isogenic HNSCC cell 
lines. 
We observed an increase of apoptosis by ectopic expression of Noxa in all 
HNSCC cell lines tested, but not in immortalized human normal oral keratinocytes 
(NOK), suggesting that Noxa overexpression is sufficient to induce tumor-specific cell 
death. Noxa-induced cell death was mediated by BAX and BAK activation. BAK 
activation was mediated through Noxa binding to MCL-1, but not BCL-XL. Cisplatin-
resistant cells induced less Noxa and apoptosis, supporting that Noxa induction is 
prerequisite for apoptosis induced by cisplatin. Taken together, Noxa induces tumor-
specific cell death in HNSCC cells primarily through BAX and BAK activation, which 







 Cancer is initiated by a modification of the genes that primarily control how cells 
proliferate and survive. Cancer is one of the leading causes of death worldwide and its 
prevalence has increased over the past decade. There were 14 million new cases in 2012, and the 
estimated number of new cases is 22 million by 2032 [www.cancer.gov]. The most common 
types of cancer among men and women include lung, head and neck, prostate, colorectal, 
stomach, liver, breast, and uterine cervix cancer [www.who.org]. With this estimated increase in 
new cases, it is critical that we continue to make progress in our understanding of the molecular 
mechanisms of tumorigenesis and cell death.  
 While genetic alterations cause cancer development, there are many environmental 
factors that also play a role in the risk of this disease. Such environmental factors include, but are 
not limited to alcohol, radiation, sunlight, and tobacco. Alcohol consumption is believed to 
increase ones risk of mouth, throat, esophagus, larynx, liver, and breast cancer 
[www.cancer.gov]. Ionizing radiation contains wavelengths with enough energy to cause DNA 
damage, which ultimately leads to cancer [www.cancer.gov]. One prominent radiation threat is 
the sunlight, which emits UV radiation that over time has the potential to damage skin cells and 
increases a person’s risk of skin cancer. Tobacco use is known to cause a variety of cancers, 
which include lung, larynx, mouth, esophagus, throat, bladder, kidney, liver, stomach, pancreas, 
colon and rectum, and cervical cancer [www.cancer.gov]. Tobacco products such as cigarettes 
and smoke emitted by their usage contain many harmful chemicals that result in DNA damages. 
While these are some of the primary causes of cancer, there are many other risk factors of 
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developing cancer such as human immunodeficiency virus (HIV), human papillomaviruses, 
bacteria, hormones, diet, obesity, and age.  
 
1.2 Head and neck cancer 
 Head and neck cancer is a phrase used to describe a number of different malignant 
tumors that arise in the oral cavity, pharynx, larynx, paranasal sinuses, nasal cavity, and salivary 
glands [2].  Typically these cancers originate in the squamous cells that line mucosal surfaces 
within head and neck [www.cancer.gov]. For this reason, these cancers are often referred to as 
head and neck squamous cell carcinomas (HNSCC). HNSCC is the sixth leading cancer 
worldwide and includes symptoms such as a bump or sore that does not heal, throat irritation, 
and difficulty of swallowing [www.cancer.gov]. Head and neck cancers make up 3 percent of all 
documented cancers in the United States [3], and occur twice as much in men as they do in 
women [1]. HNSCC is diagnosed most often in individuals over the age of 50, many of whom 
have been exposed to one or more of the risk factors [www.cancer.gov]. The survival rate for 
individuals diagnosed with head and neck cancer is about 50 percent, and has not changed much 
in the last 50 years [www.mcancer.org]. It is estimated in year 2016 that 59,340 people will be 
diagnosed with head and neck cancer and about 12,290 deaths will occur due to the disease 
[www.cancer.net].  
 The primary risk factors for head and neck cancer include the use of tobacco and 
consumption of alcohol, which are estimated about 75 percent of this cancer [4-7]. Studies have 
shown a direct correlation to the increased use of either one of these carcinogens and an 
individual’s risk of developing cancer within the oral cavity, pharynx, larynx, and esophagus [9]. 
Another risk factor that has been seen more readily over the past 20 years is human 
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papillomavirus-16 (HPV-16). This virus often leads to cancers at the back of the tongue and 
tonsil region, and is spread mainly through oral sex [10].  
 Before treating individuals with HNSCC, doctors usually perform an assessment to the 
cancer to determine the place, the stage, its size, and patient’s overall health. Knowing the stage 
of the cancer will greatly aid doctors in choosing the best mode of treatment. To effectively 
determine the stage of tumor, doctors use the TNM system to place the tumor anywhere from 
stage zero to stage five. The TNM system considers the tumor size, possible spread of the tumor 
to lymph nodes, and possible metastasis to other parts of the body [www.cancer.net]. Stage 0 
tumor grows only in the location of head and neck where it originates, and has not yet spread to 
deeper tissue layers or more distant structures. Stage I tumors are estimated to be 2 cm in 
diameter or smaller, and no other cancer cells are present in surrounding tissues or distant 
structures. Stage II tumors measure 2-4 cm in diameter, yet no cancer cells are present in 
surrounding tissues or distant structures. Stage III tumors have grown even larger to 4 cm in 
diameter or greater. Once reaching stage IV, there are three sub-stages in which the patient may 
be classified. Stage IVA tumors may be any size and grow into localized structures including 
lymph nodes on the same side of the primary tumor of head and neck. Stage IVB tumors invade 
deeper tissues and have spread to lymph nodes but not into distant areas. Stage IVC tumors are 
any size and have spread to lymph nodes as well as distant areas of the body 
[www.cancercenter.com].   
The main goal of the doctors is to remove or destroy all of the tumors with the least 
toxicity to the patient. There are several different treatment options such as surgery, radiation 
therapy, and chemotherapy. For patients with early stage tumor (I or II), surgery or radiotherapy 
is often used for treatment. In those more progressed patients (stage III or IV), treatment may 
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consist of surgery, radiotherapy, and chemotherapy. Types of chemotherapeutic drugs that are 
used for head and neck cancer include docetaxel, gemcitabine, fluorouracil, carboplatin, and 
cisplatin (cisplatin being the most commonly used).  
  
1.3 Cisplatin 
  Cisplatin, a platinum based chemotherapeutic drug with antineoplastic activity, is often 
used to treat cancers that are metastasized or advanced and unable to be treated by other methods 
such as surgery or radiation. Cisplatin is widely used to treat cancers including: head and neck, 
small cell lung cancer, sarcoma, germ cell tumors, lymphoma, and ovarian cancer. Cisplatin (cis-
[Pt(NH3)2(Cl)2]) was created in 1845 by Michele Peyrone, who originally named the compound 
as Peyrone’s chloride. It wasn’t until the mid-1900s that Barnett Rosenberg and his colleagues 
demonstrated cisplatin’s ability to inhibit cell division and reduce the size of solid tumors [11,55]. 
However, even today the complete mechanism as to how cisplatin induces cell death in cancer 
cells is not fully understood. 
  Cisplatin is composed of 11 atoms with platinum in the center (Figure 1) [8]. Once 
intravenously injecting cisplatin, the chemical undergoes aquation to form [Pt(NH3)2Cl(OH2)]+ 
and [Pt(NH3)2(OH2)2)]2+. The platinum atom of cisplatin covalently binds to the N7 position of 
purines to form 1,2- or 1,3-intrastrand crosslinks [14,15]. Cisplatin-DNA adducts result in various 
cellular responses including replication arrest, transcription inhibition, cell-cycle arrest, DNA 
repair and apoptosis (Figure 2) [13]. The most common form of cell death seen is through the 
induction of BCL-2 family-dependent mitochondrial apoptosis and subsequent caspase-3 
activation. While the drug does offer strong antitumor effects, it is similar to other 
chemotherapeutic agents in that its use over a prolonged period of time is limited due to the 
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Figure 2: Cellular processing of cisplatin. Formation of cisplatin and its crosslinking with 




1.4 Cell death 
  Cell death can be categorized into many categories including apoptosis, autophagy, or 
necrosis through the analysis of morphological appearances demonstrated by cells as they 
progress through the pathway. Apoptosis, also known as type I programmed cell death, occurs as 
a result of caspase activation. With morphological changes, apoptosis is characterized by 
rounding-up of the cell, retraction of pseudopods, shrinkage, chromatin condensation, nuclear 
fragmentation, chromosomal DNA fragmentation, and some plasma membrane blebbing. Dying 
cells proceed through a mechanism that is reversible until a step occurs at which cells have no 
choice but to die. It is believed that the irreversible step for apoptosis is represented by outer 
mitochondrial pore formation and permeabilization. Meanwhile, autophagy and necrosis often 
transpire through caspase-independent pathways. Autophagy is a type of cell death that happens 
in the absence of chromatin condensation, but in the presence of autophagic vacuolization in the 
cytoplasm. Necrosis is characterized by a gain in cell volume, swelling of organelles, plasma 
membrane rupture, and loss of intracellular contents. Necrosis is mostly associated with an 
unregulated form of cell death that occurs as a result of some pathological condition. However, 
necroptosis is a term that has been coined to describe a type of regulated necrosis that involves 
signaling through the kinase RIP1 [16]. 
  Throughout life, the body must maintain homeostasis; one way is though initiating 
apoptosis to balance out the amount of cell proliferation with cell death. This type of cell death is 
very important in tissues such as intestinal epithelium and the hematopoietic system, which 
experience a high turnover rate [17]. Being the most common form of cell death, apoptosis is often 
the targeted pathway to induce cell death in tumors.  
  Research suggests that the apoptotic pathway can be divided into two main pathways: the 
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intrinsic or mitochondrial pathway and the extrinsic or death receptor pathway [17]. The intrinsic 
pathway can be triggered by various stressful stimuli such as chemotherapeutic drugs that cause 
the cell to initiate apoptosis. The BCL-2 family proteins (Details are described below) regulate 
this pathway; they act in a way that alters the outer mitochondrial membrane permeability and 
allows the release of cytochrome c into the cytosol. Once released, cytochrome c binds to the 
apoptotic protease-activating-factor 1 (APAF-1) that forms an oligomeric apoptosome. The 
apoptosome then forms a complex with pro-caspase-9 and cleaves it to release its active form. 
Activated caspase-9 then acts on other caspase cascades, the most notable of these being 
caspase-3 activation, which then commits the cell to apoptosis [www.ncbi.nlm.nih.gov]. For the 
extrinsic pathway, death ligands such as tumor necrosis factor-α (TNF-α), CD95 ligand (Fas 
ligand), and TNF-related apoptosis-inducing ligand (TRAIL), bind to their respective cell-
surface receptors, which results in trimerization of the receptors and recruitment of adapter 
proteins. This newly formed complex recruits caspase-8, which is activated (cleaved) and then 






















Figure 3: Simplified diagram of the intrinsic and extrinsic apoptotic pathways [50].  
 
1.5 BCL-2 family proteins 
  The BCL-2 family members play key roles in the regulation of apoptosis through the 
mitochondrial pathway via protein-protein interactions, which results in inhibition or induction 
of cell death. These interactions occur between functionally and structurally distinct subgroups at 
the outer mitochondrial membrane. These subgroups are described as the BH3 (BCL-2 
homology 3)-only pro-apoptotic proteins and core BCL-2 family proteins, which contain three or 
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four BH domains (BH1-BH4). The latter is subdivided into pro-survival and multi-domain pro-
apoptotic proteins. These multi-domain pro-survival and pro-apoptotic proteins all share four BH 
domains. The sequence homology between pro-survival proteins suggests that all of them exhibit 
a similar fold, where functionally important regions (BH1, BH2, and BH3) are in close spatial 
proximity [19]. The fold produces a hydrophobic pocket or groove that establishes a crucial 
interface for interactions with the BH3 domain of pro-apoptotic members of the BCL-2 family.  
  BAX and BAK make up the multi-domain pro-apoptotic protein group and upon 
activation (conformational change), they oligomerize and form a pore in the outer mitochondrial 
membrane. This mitochondrial outer membrane permeability (MOMP) pore allows the release of 
cytochrome c into cytosol and subsequent caspase-dependent apoptotic events to occur.  Multi-
domain pro-survival proteins consist of BCL-2, MCL-1, BCL-XL, BCL-W, and A1 (also known 
as BFL1 in humans), which act to neutralize or restrain BAX and BAK by protein-protein 
interactions. 
  The BH3-only pro-apoptotic protein group consists of Noxa, BAD, BID, BIM, and 
several others, which are induced transcriptionally or post-translationally upon the exposure to 
cytotoxic stresses that exceed the apoptotic threshold. These BH3-only proteins act in two ways: 
to neutralize pro-survival proteins or directly activate BAX and/or BAK. To neutralize pro-
survival proteins, the BH3-only protein’s BH3 amphipathic helix binds to the hydrophobic 
pocket of pro-survival proteins (BCL-2, BCL-XL, MCL-1), which prevents these pro-survival 
proteins from interfering with BAX and BAK oligomerization for pore formation. BID and BIM 
are the BH3-only proteins that seem to have the unique ability of directly activating BAX and 
BAK to induce apoptosis. Due to subtle differences in BH3-only protein’s BH3 domains and the 
grooves to which they bind, some BH3-only proteins such as BAD (BCL-2 antagonist of cell 
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death) and Noxa are selective for the binding to specific pro-survival proteins. For example, 
Noxa has a much stronger affinity for MCL-1 (myeloid cell leukemia sequence 1) over any of 
the other multi-domain pro-survival proteins such as BCL-2 or BCL-XL.  
  BAX and BAK proteins act in a similar manner to the BH3-only proteins in that they can 
bind to the hydrophobic pocket of multi-domain pro-survival proteins with their BH3 domain [49]. 
However, upon increased expression levels of BH3-only proteins, competition increases between 
the BH3-only proteins and the pro-survival proteins, which causes an increased rate of apoptosis.  
  In healthy cells, BAK is located at the mitochondria and is restrained by MCL-1 or BCL-
XL. BAX is located predominantly in the cytosol and restrained by a variety of the pro-survival 
proteins, but upon activation by cytotoxic stimuli, it gets relocated to the outer mitochondrial 





Figure 4: A list of the BCL-2 family proteins. Proteins are separated into pro-survival and pro-
apoptotic groups. The major differences between the proteins are the number of BH domains that 
they contain [20]. 
 
1.6 MCL-1 and Noxa 
  MCL-1 was discovered in 1993 in differentiating myeloid cells [21]. Since then, MCL-1 
has been shown to play a key role in the regulation of apoptosis and cell survival in immortalized 
and tumor cells. The protein is composed of 350 amino-acid residues in human and shares 
several BH domains with other BCL-2 family members. While BCL-2 and BCL-XL contain BH 
domains 1-4, MCL-1 lacks BH4 domain. The structure of MCL-1 protein contains a C-terminal 
transmembrane domain that functions to localize MCL-1 to various intracellular membranes, 
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with the most common being the outer mitochondrial membrane [22]. The N-terminus of MCL-1 
is comprised of two PEST domains, which are quite prevalent in rapidly turned over proteins. 
This rapid turnover rate can be greatly attributed to the ubiquitin-proteasome pathway. While 
MCL-1 expression levels vary among cells, the more differentiated apical layers of epithelia such 
as prostate, breast, colon, and lung epithelia, tend to have the highest levels [23]. Expression levels 
of MCL-1 are determined by various cytokines and growth factors, which signal to the cell to 
survive and differentiate [24]. Many pathways have been shown to induce transcription of MCL-1 
through the specific transcription factor response elements in the promoter region of MCL-1, 
such as mitogen-activated protein kinase (MAPK), phosphatidylinositol-3 (PI3K), and Janus 
kinase (JAK)/signal transducer and activator of transcription (STAT) [24,25]. Furthermore, direct 
phosphorylation sites along the PEST domain also control the expression levels of MCL-1. 
During apoptosis MCL-1 is often down-regulated, which could be a result of caspase cleavage. 
Activated effector caspases have the ability to cleave MCL-1 at the N-terminal end within the 
PEST domain. Upon cleavage, MCL-1 pro-survival function is lost, and it can no longer 
sequester BAK to prevent apoptosis. Overall, MCL-1 is a highly regulated protein and its 
expression levels are often in direct correlation with cell death and survival.  
  Noxa, which was identified in 2000 as a p53 target gene, is composed of 54 amino-acid 
residues in human. The protein is a pro-apoptotic BH3-only protein that also contains a 
mitochondrial targeting domain at the C-terminus end. Under cytotoxic stress, Noxa has been 
shown to localize to the outer mitochondrial membrane, where its BH3 domain sequesters and 
binds to pro-survival BCL-2 family member MCL-1. This recruitment of MCL-1 initiates its 
phosphorylation at Ser64/Thr70 sites and subsequent ubiquitination, which results in 
proteasome-mediated degradation [28,33]. This Noxa-mediated phosphorylation of MCL-1 occurs 
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at the mitochondria and is predominantly regulated by CDK2 [33]. Furthermore, the Noxa/MCL-1 
interaction is sufficient to inhibit the function of MCL-1, and causes the release of BAK and 
subsequent activation (conformational change). Upon activation, BAK is able to oligomerize and 
form a pore in the outer mitochondrial membrane. Cytochrome c is then released into the 
cytosol, which ultimately results in caspase-9 activation. To confirm that Noxa plays a critical 
role in the induction caspase-dependent apoptosis, endogenous Noxa induction was blocked, 
which correlated with a decrease in the levels of apoptosis. It has been demonstrated that Noxa is 
capable of being induced by p53-dependent or -independent apoptosis [26]. For example, the use 
of a DNA damaging agent cisplatin results in p53-dependent Noxa up-regulation, but under 
hypoxic conditions HIF1α is capable of inducing Noxa independent of p53 [29,31].  
 
1.7 Clinical problem  
  Over the past three decades, there have been minor advancements with the treatment 
success of patients diagnosed with head and neck cancer. While treatment options are becoming 
more personalized from patient to patient, more often than not the three types of standard 
treatment are used (surgery, radiation, chemotherapy). If the tumor is diagnosed as a stage II-IV, 
a chemotherapeutic drug such as cisplatin is commonly used to shrink the tumor before radiation 
or surgery is performed. While cisplatin usage normally results in initial reduction in tumor size, 
one of the major problems regarding the use of cisplatin is the cancer’s ability to develop a 
clinical drug resistance. This cellular drug resistance may occur as a result of any of the 
following: 1) decreased uptake of cisplatin, 2) increase in metallothioneins (MT), 3) increase in 
glutathione and/or glutathione-S-transferase, 4) increased DNA repair, or 5) increased tolerance 
to unrepaired DNA lesions [34]. The factors listed have a plethora of mechanisms associated with, 
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which makes it difficult to pinpoint exactly where the cisplatin-resistant phenotype of cancer 
cells derives from. Furthermore, the mutations that make these cells resistant may vary between 
cell types and patients.  
  To overcome the acquired resistance, researchers are currently focusing on the discovery 
of potential molecular targets for cancer therapy. One example of a molecular target is the 
epidermal growth factor receptor (EGFR). EGFR is a well-documented proto-oncogene that 
promotes tumor progression and its expression levels are elevated in >95% of HNSCCs [35]. With 
this knowledge, EGFR seems to be a good target for patients with acquired cisplatin resistance. 
EGFR-targeted therapies include the use of monoclonal antibodies (mAb) and tyrosine kinase 
inhibitors (TKIs). Monoclonal antibodies serve to block the extracellular ligand-binding domain 
and the TKIs inhibit the activation of the cytoplasmic tyrosine kinase of EGFR [35]. However, 
unless paired with a high-dose of radiation, the EGFR-specific mAb (cetuximab) or TKIs alone 
provides only a limited efficacy [36,37]. Therefore, researchers have continued to search for other 
molecular targets to overcome acquired resistance to chemotherapeutic drugs such as cisplatin.  
 
1.8 BCL-2 inhibitor  
  After studying the genetic background of various drug resistances in hematopoietic 
malignancies and solid tumors, the overexpression of pro-survival BCL-2 family proteins are 
often implicated [39-41]. For this reason, research has quickly started focusing on developing small 
molecule inhibitors exclusive for pro-survival BCL-2 proteins. By using these small molecule 
inhibitors in combination with cisplatin, doctors may be able to lower the toxicity of the 
treatment by reducing the amount of cisplatin used [38]. These BCL-2 protein inhibitors are 
developed to mimic the BH3 domain of BH3-only pro-apoptotic proteins. The small molecule 
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inhibitors are designed to compete with the already present BH3-only proteins for binding to pro-
survival BCL-2 proteins, which cause a release and activation of BAX and BAK. These BCL-2 
inhibitors do not directly trigger cytochrome c release from the mitochondria, but rather decrease 
the cellular apoptotic threshold, which makes them useful when in combination with standard 
therapies.  
  One of these small molecule inhibitors is ABT-737 and orally bioactive ABT-263, which 
have sub-nanomolar affinities for BCL-2 and BCL-XL but not for MCL-1. Like other BCL-2 
inhibitors, ABT-263 requires BAX and BAK function within the targeted cancer for the drug to 
be effective [38]. Research has shown that ABT-263 is specific to tumor cells and therefore serves 
to keep low cytotoxic levels within the patient. However, the main issue with ABT-263 is that it 
does not have a strong affinity for MCL-1, which is known to be a key anti-apoptotic protein in 
tumor cells. Future research may lead to the development of a small molecule inhibitor that has 
strong affinity for MCL-1. Combination therapy with the use of ABT-263 and another MCL-1 













 Cisplatin induces antitumor effects through several mechanisms, although the most 
notable mechanism involves the generation of DNA lesions that result in induction of BCL-2 
family-dependent mitochondrial apoptosis. One of these BCL-2 family pro-death proteins that 
are induced is Noxa, which binds to pro-survival BCL-2 family protein MCL-1, to inactivate its 
function and release pro-death protein BAK to induce apoptosis. We hypothesize that Noxa 




















3.1 Determine the molecular mechanisms by which Noxa induces cell death in HNSCC cells. 
 Cisplatin toxicity levels on eight HNSCC cell lines will be measured. Lentivirus-
mediated shRNA (knockdown of Noxa) will be introduced to examine the involvement of Noxa 
in cisplatin-induced cell death. Noxa will be overexpressed in eight HNSCC cell lines by 
lentivirus-mediated transfection. Knockdowns of pro-apoptotic BAX and/or BAK will be 
conducted with lentivirus-mediated shRNA to determine their function in Noxa-mediated cell 
death. Protein interaction among BCL-2 family members will be examined by 
immunoprecipitations followed by Western blot analysis. Cell death will be determined by 
Western blot analyses or Annexin V-propidium iodide (PI) staining followed by fluorescence-
activated cell sorting (FACS) analyses.  
 
3.2 Determine the molecular mechanism of cisplatin-resistant isogenic HNSCC cell lines. 
 Cells will be treated with cisplatin over a prolonged period of time to mimic tumor-
acquired resistance seen in patients. Cells will be infected with lentivirus harboring Flag-tagged 
Noxa cDNA to overexpress Noxa and see if cell death sensitivity is recovered. Cell death will be 
analyzed using Western blot analyses and Annexin V-propidium iodide (PI) staining followed by 







MATERIALS AND METHODS 
4.1 Cell lines and cell culture  
HN4, HN12, HN22, HN8, HN30, and HN31 head and neck squamous cell carcinoma (HNSCC) 
cells were provided by Dr. Andrew Yeudall (Augusta University, GA), UMSCC1 and UMSCC6 
cells were provided by Dr. Yue Sun (Virginia Commonwealth University), and normal oral 
keratinocytes (NOK) were provided by Dr. Oonagh Loughran (Virginia Commonwealth 
University). All cell lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Life 
Technologies) with addition of 10% heat-inactivated fetal bovine serum (FBS) (Gemini Bio-
Products, West Sacramento, CA) and 5% 100 µg/mL penicillin G/streptomycin (Invitrogen) at 
37°C in a humidified, 5% CO2 incubator. 293T cells were purchased from the American Type 
Culture Collection (Manassas, VA). HN30/sh-Noxa, HN31/sh-Noxa, HN31 shC, HN31 shBAX, 
and HN31 shBAK cells were maintained with 2 µg/mL of puromycin (InvivoGen, San Diego, 
CA) for selection.  
 
4.2 Plasmid transfection and lentivirus infection  
The lentiviral short-hairpin RNA (shRNA) expressing constructs were purchased from Open 
Biosystems (Huntsville, AL) or Sigma-Aldrich (St. Louis, MO). Flag-tagged Noxa cDNA was 
cloned into pCDH-EF1-MCS-IRES-neo (System Biosciences, Mountain View, CA). The 
constructs were transfected into 293T packaging cells along with the packaging plasmid 






4.3 Chemicals and antibodies 
Cisplatin (sc-200896) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 
Antibodies for BIM, BCL-XL (54H6), Cleaved PARP (Asp214), GAPDH (D16H11), Cleaved 
Caspase -3 (Asp175), HRP-linked anti-mouse IgG, and HRP-linked anti-rabbit IgG were from 
Cell Signaling Technology (Beverly, MA); MCL-1 (ADI-AAP-240-F) from Enzo Life Sciences 
(Farmingdale, NY); Alpha-Tubulin (sc-8035), BAX (sc-493), and p53 (sc-126) from Santa Cruz 
Biotechnology (Santa Cruz, CA); Monoclonal BAK (AB-1) and BAK (06-536) from Millipore 
(Darmstadt, Germany); Noxa (114C307.1) from Thermo Fisher Scientific (Waltham, MA); 
Monoclonal Anti-BAX (6A7) and BCL-2 (B3170) from Sigma-Aldrich (Saint Louis, Missouri). 
ECL 2 Western blotting substrate (80196) was purchased from Thermo Scientific (Rockford, IL). 
Cell proliferation reagent WST-1 was purchased from Roche Diagnostics (Mannheim, 
Germany).  
 
4.4 Western blot and immunoprecipitation analysis  
To perform Western blots, whole HNSCC cell lysates were prepared with CHAPS lysis buffer 
[20 mM Tris (pH 7.4), 137 mM NaCl, 1 mM dithiothreitol (DTT), 1% CHAPS (3-[(3-
Cholamidopropyl) dimethylammonio]-1-propanesulfonate), 1:200 ratio of protease inhibitor 
cocktail (Sigma Aldrich), and 1:100 ratio of phosphatase inhibitor cocktails 2 and 3 (Sigma)]. 
Protein concentrations from the lysates were measured by spectrophotometric analysis with the 
Bradford method (Bio-rad, Hercules, CA), and equal amounts of samples were loaded into SDS-
polyacrylamide gels. The gel was electrophoresed at 180 volts for approximately 45 minutes and 
the proteins were transferred onto a nitrocellulose membrane (Fischer Scientific, Pittsburgh, PA) 
with 100 volt for one hour. The nitrocellulose membrane was then blocked with a blotting 
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solution [5% skim milk in PBST (1 x PBS with 0.1% Tween-20)] for 20 minutes, and specific 
primary antibodies were incubated with the membrane for overnight at 4°C. The incubated 
membrane was washed with PBST for at least five minutes for three times and then either HRP-
linked anti-mouse IgG or anti-rabbit IgG antibodies were incubated with the membranes for one 
hour at room temperature. The membranes were washed three times with PBST for five minutes. 
The membrane was then developed using Pierce ECL- 2 Western Blotting Substrate (Thermo 
Fisher Scientific).  
To perform immunoprecipitation (IP), 500 µg of protein sample was prepared to match a total 
volume to be 500 µL. The samples were then incubated with the appropriate antibodies for 
overnight on a rotating table at 4°C. After the incubation, 25 µL of agarose beads with Protein 
A/G UltraLink Resin (Thermo Fisher Scientific) were added and incubated for 1 hour at 4°C. 
Supernatants were then removed by centrifugation for 30 seconds at 6000 rpm and 1 mL of 
CHAPS buffer was added and incubated again on the rotating table for 5 minutes at 4°C. This 
step was repeated three times. All of the supernatant was aspirated and then the beads were re-
suspended with 15 µL of 5x sample buffer. The samples were loaded to SDS-PAGE gels.  
 
4.5 Cell toxicity (WST-1) assay  
Head and neck squamous cell carcinoma cells were seeded in triplicate in microtiter plates (96 
wells) with 1x104
 
cells per well in 150 µL medium. The following day, cells were treated with 
different concentration of cisplatin and 48 hours later, 2 µL of WST-1 reagent were added to the 
cells. The WST-1 assay is based on tetrazolium salt WST-1 (4-[3-(4-iodophenyl)-2-(4-
nitrophenyl)-2H-5-tetrazolio]-1, 3- benzene disulphonate). It is used to determine the 
cytotoxicity of cisplatin by measuring the absorbance of the samples with a microplate enzyme-
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linked immunosorbent assay (ELISA) reader (Promega Life Sciences).  
 
4.6 IC50  
IC50 (half maximal inhibitory concentration) is a term that represents an amount of specific 
substance (inhibitor) needed to inhibit 50 percent of cell’s biological or biochemical 
mechanisms, i.e. an enzyme, receptors or microorganism. IC50 for cisplatin cytotoxicity was 
calculated for each HNSCC cell line by obtaining quantitative measurements from the microplate 



















5.1 HNSCC cell lines and their cisplatin sensitivity, IC50 
  Table 1 contains a list of head and neck squamous cell carcinoma cell lines that were 
used in this study. The IC50 of the cell lines with cisplatin treatment was analyzed with WST-1 
assay. WST-1 (tetrazolium salt) is cleaved to form soluble formazan when cells are metabolically 
active, which can then be quantitated with a scanning multi-well spectrophotometer at 450nm 
(Figure 5).  
  It was found that p53 mutated cell HN31, and p53 wild-type cells, HN30 and UMSCC1 
possessed the lowest IC50. p53 truncated cells, HN4 and HN12 had the highest IC50, and p53 
deleted cells, HN22, HN8 and UMSCC6 had an IC50 between p53 truncated and p53 wild-type 















TABLE 1. HNSCC Cell Lines 
Patient Cell Line Origin p53 Status IC50 (µM) 
Cisplatin 
A 
HN4 Base of Tongue Truncated 
(Non-functional) 
75 




HN22 Epiglottis Deleted 50 
HN8 Lymph node Deleted 50 
C 
HN30 Pharynx Wild-type 21 
HN31 Lymph node Mutated 20 
D UMSCC1 Floor of mouth Wild-type 15 
E UMSCC6 Base of tongue Deleted 40 
 
Table 1: Cell lines harvested from the lymph node are post-metastatic. The p53 genes in HN4 
and HN12 cells contain a mutation at the splicing donor site of exon 7 [32], thus p53 is truncated 
and non-functional. HN31 contains a mutation within the p53 gene, but the gene retains some 
function [54]. The p53 genes in HN22, HN8, and UMSCC6 cells are deleted, but HN30 and 




















Figure 5: Cleavage of the tetrazolium salt WST-1 to formazan. (EC=electron coupling 





























































Figure 6: IC50 of cisplatin treatment in HNSCC cell lines. Cell proliferation was determined 
by the WST-1 assay. HNSCC cell lines were treated with different concentrations of cisplatin for 
48 hours. The results are the mean ±S.D. of triplicates. (a) HN4  (b) HN12  (c) HN22  (d) HN8  





5.2 Induction of Noxa is required to induce apoptosis under cisplatin treatment in HNSCC 
cells 
  To examine whether Noxa up-regulation is required for cisplatin-induced cell death, we 
introduced short-hairpin RNA (shRNA) for Noxa to down-regulate Noxa expression. For a 
control we used a non-targeting shRNA. HN31 cells that stably expressed sh-control (sh-C) or 
sh-Noxa were seeded in 6-well plates and treated with cisplatin in each well (20 µM). Cells were 
harvested at 0, 2, 4, 8, 16, and 24 hour time points and probed with cleaved-PARP, MCL-1, and 
Noxa. Cleaved-PARP is one target protein of active caspase-3, which is cleaved (activated) 
during caspase-dependent apoptosis. Under sh-Noxa conditions there is a noticeable reduction in 
cleaved-PARP, indicating a reduction in apoptosis (Figure 7). This result indicates that Noxa is 







Figure 7: Cisplatin treated HN31 Noxa knockdown. HN31 cells were infected with lentivirus-
encoding shRNA for non-targeting control or Noxa. The cells were then treated with cisplatin 
(20 µM) for the indicated periods. Equal amounts of total lysates were subjected to Western blot 
analysis using indicated antibodies. Alpha-tubulin was used to confirm equal loading of total 





5.3 Noxa overexpression results in the induction of cell death in HNSCC cells 
  Previous research has shown that treatment of HNSCC cells with cisplatin leads to up-
regulation of Noxa, which results in the sequestration and subsequent degradation of pro-survival 
protein MCL-1 [49]. Therefore, up-regulation of Noxa alone may be enough to induce cell death 
in HNSCC cells. To investigate this we infected HNSCC cell lines with lentivirus-encoding 
Flag-tagged Noxa and an empty vector as a control. The cells were harvested after 24 hours of 
incubation and Western blot analysis was utilized to examine protein expression levels. In all 
HNSCC cell lines tested, we observed an increase of cleaved-PARP, which is an indication that 
Noxa overexpression alone is capable of inducing apoptosis (Figure 8).  
 
 
Figure 8: Overexpression of Noxa induces cell death in HNSCC cell lines. HNSCC cell lines 
were infected with lentivirus-encoding Flag-tagged Noxa cDNA or an empty vector as a control. 
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Following 24 hours of incubation the cells were harvested and equal amounts of total lysates 
were subjected to Western blot analysis with antibodies listed. GAPDH was used as a loading 
control for HN4, HN12, UMSCC1, and UMSCC6, whereas alpha-tubulin was used for HN22, 
HN8, HN30, and HN31. [-: control, wt: Noxa wild-type (overexpression)] (HN4, HN12, HN22, 
HN8, HN30, & HN31 [53]) 
 
5.4 Noxa overexpression induces apoptosis only in HNSCC cells but not in Normal Oral 
Keratinocytes (NOK)   
  Knowing that Noxa overexpression induces cell death in HNSCC cell lines, we decided 
to infect immortalized normal oral keratinocytes (NOK) using lentivirus-encoding Flag-tagged 
Noxa cDNA or an empty vector as a control. The amount of apoptosis was determined by 
Western blot analyses with cleaved-PARP antibody. NOK clearly exhibited less induction of 
cleaved-PARP compared to HN8 and HN31 cell lines (Figure 9a). Furthermore, a crystal violet 
staining assay was performed with HN31 cells and NOK. HN31 and NOK were infected with an 
empty vector as a control and Flag-tagged Noxa cDNA. Crystal violet staining assay indicated 
that there was a significant amount of live NOK when overexpressing Noxa compared to HN31 


















Figure 9: Noxa overexpression induces tumor-specific cell death. (a) NOK, HN8, and HN31 
cells were infected with lentivirus-encoding Flag-tagged Noxa cDNA or an empty vector as a 
control. Following 24 hours of incubation, the cells were harvested and equal amounts of total 
lysates were subjected to Western blot analysis with antibodies listed. GAPDH was used as a 
loading control in all cell lines. (b) HN31 and NOK were seeded in a 96 well plate and infected 
with lentivirus-encoding Flag-tagged Noxa cDNA or an empty vector as a control. Seventy-two 
hours after the infection, cells were stained with crystal violet to quantitate the amount of cells 









5.5 Functional BH3-domain is required for Noxa-induced cell death and binding to MCL-1 in 
HNSCC cells 
  Since Noxa is a BH3-only protein, we examined whether a functional BH3-domain is 
required for Noxa-induction of cell death. Therefore, we created three amino acid mutations 
within the BH3-domain of Noxa (3E mutant). Hydrophobic leucines and phenylalanine in the 
BH3 domain were replaced with hydrophilic glutamic acids to prevent α-helical structure (Figure 
10b). HN31 and HN8 cell lines were infected with lentivirus-encoding 3E cDNA, Noxa cDNA 
as positive control, or an empty vector as negative control. Western blot analysis using cleaved-
PARP antibody was implemented to determine the amount of cell death. The 3E mutant infection 
to HN31 and HN8 cell lines revealed significantly less cleaved-PARP than those with Noxa 
wild-type (Figure 10a). This data suggests that a functional BH3-domain of Noxa is required to 
induce cell death through binding of MCL-1 in HNSCC cell lines. Next, we wanted to confirm 
that the reason we examined no cell death, was due to the Noxa mutated BH3 domain being 
unable to sequester and bind to MCL-1 and inhibit its function. To analyze this we infected 
HN31 cells with lentivirus-encoding Noxa wt cDNA or 3E cDNA and examined the protein-
protein interactions with immunoprecipitation followed by Western blot analysis. We observed a 
binding of MCL-1 and Noxa in the wild-type Noxa infection, but no binding of the 3E mutated 
Noxa infection (Figure 10c), suggesting that Noxa needs a functional BH3 domain to induce cell 























Figure 10: Noxa 3E mutant results in no induction of cell death. (a) HN8 and HN31 cells 
were infected with lentivirus-encoding a Noxa BH3-domain mutant (3E). Infected cells were 
harvested after 24 hours of incubation and equal amounts of total lysates were subjected to 
Western blot analysis with antibodies indicated. GAPDH was used as a loading control. [-: 
control, wt: Noxa wild-type (overexpression), 3E: Noxa protein with a mutated BH3 domain] (b) 
The amino acid sequence of human Noxa protein. The green arrows point to the amino acids that 




encoding a Flag-tagged Noxa wt cDNA and Noxa BH3-domain mutant (3E). Infected cells were 
harvested following 24 hours of incubation and an immunoprecipitation was conducted, followed 
by Western blot analysis. GAPDH was utilized as a loading control. 
 
5.6 Noxa overexpression results in reduction of MCL-1/BAK interaction and activation of 
BAK and BAX 
  Knowing that pro-survival MCL-1 and BCL-XL normally bind to and inhibit the pro-
apoptotic function of BAK, we investigated whether there would be a change in protein 
interactions upon Noxa overexpression. To do this we overexpressed Noxa in HN31 cells by 
infecting them with lentivirus-encoding Flag-tagged Noxa cDNA or an empty vector as a 
control. To analyze the protein-protein interactions we conducted an immunoprecipitation 
followed by Western blot analysis. We observed a decrease in MCL-1 and BAK interaction 
when Noxa was overexpressed, suggesting that Noxa is causing the release of BAK upon its 
binding to MCL-1 (Figure 11a). At the same time we saw that BCL-XL and BAK interaction is 
unchanged by Noxa overexpression, indicating that Noxa is primarily acting through its 
sequestration of MCL-1.  
  In healthy cells BAX and BAK adopt globular α-helical structures as monomers, which 
hide their N-terminus portion of the protein. Following a variety of stress signals such as 
cisplatin treatment or Noxa overexpression, they undergo a conformational change (activation), 
allowing them to become pore-forming proteins of the outer mitochondrial membrane. During 
this conformational change of BAX and BAK, their N-terminus becomes exposed. To confirm 
that BAK is activated when released from MCL-1, we used a monoclonal N-terminus specific 
antibody for immunoprecipitation and then analyzed the change of protein activation with a 
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Western blot (Figure 11b). When overexpressing Noxa, BAK underwent strong activation. We 
also analyzed BAX activation under Noxa overexpression by using an N-terminus specific 
antibody for immunoprecipitation followed by Western blot analysis (Figure 11c). The result 
indicated a substantial increase in BAX activation, suggesting that Noxa is able to influence the 
amount of activated BAX. We then examined the possibility whether Noxa overexpression 
changed the interaction of BAX and MCL-1 in HN31 cells. We confirmed this by performing 
immunoprecipitation followed by Western blot analysis. We observed that the interaction 
between MCL-1 and BAX was undetectable in HN31 cells either with an empty vector or with 



























Figure 11: Immunoprecipitations to analyze BCL-2 family interactions and activation 
following Noxa overexpression. HN31 cells were infected with lentivirus-encoding Flag-tagged 
Noxa cDNA or an empty vector as a control. The infected cells were harvested after 24 hours of 
incubation. GAPDH was used for all Western blots to confirm equal amounts of total lysate 
loaded for the experiment. (a) HN31 infected cells were harvested and immunoprecipitation was 
performed with a BAK antibody followed by Western blot analysis with indicated antibodies. (b) 
HN31 infected cells were harvested to analyze BAK activation. Total cell extracts were 
subjected to immunoprecipitation with BAK (conformational specific) antibody followed by 
Western blot analysis with the indicated antibodies. (c) HN31 infected cells were harvested to 
analyze BAX activation. The harvested cells were used for immunoprecipitation with a BAX 
(conformational specific) antibody followed by Western blot analysis with indicated antibodies. 
(d) HN31 infected cells were harvested and immunoprecipitation was performed with an MCL-1 
antibody. Immunoprecipitated extracts and total lysates were then loaded into a Western blot to 
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examine the interaction of MCL-1 and BAX. [-: control, wt: Noxa wild-type (overexpression)]  
 
5.7 Down-regulation of BAX and BAK inhibits cell death induced by Noxa overexpression 
  With a clear increase in BAK and BAX activation by Noxa overexpression in HNSCC 
cells, we then investigated the contribution of each protein to Noxa-induced cell death. To 
examine this we infected HN31 cells with lentivirus-encoding short-hairpin RNA (shRNA) for 
non-targeting sh-control (shC), BAX, or BAK to establish cells with stable knockdowns. The 
HN31 shC, shBAX, and shBAK cells were seeded in a 6 well plate and infected with lentivirus-
encoding Flag-tagged Noxa cDNA or an empty vector as a control. Cells were harvested and cell 
death was analyzed with Western blot analyses (Figure 12a). Both HN31 shBAX and shBAK 
cells showed a reduction of cleaved-PARP compared to HN31 shC cells. This data suggests that 
both BAX and BAK play roles in Noxa-mediated cell death. Moreover, we conducted a double-
knockdown experiment in which both BAX and BAK were down-regulated. The stable HN31 
shBAX cells were seeded in a 6 well plate and then infected lentivirus with shBAK to achieve a 
transient knockdown while using shC as a control. Twenty-four hours later, the cells were 
infected with lentivirus-encoding Flag-tagged Noxa cDNA or empty vector as control. Another 
24 hours later, the cells were harvested and equal amounts of total lysates were subjected to 
Western blot analysis (Figure 12b). The double-knockdown of BAX and BAK in HN31 cells 
resulted in no induction of cleaved-caspase-3, which is an indicator of apoptosis. This result 
suggests that Noxa is primarily inducing cell death through both BAX and BAK activation in 







Figure 12: Knockdown of BAX and BAK reduces Noxa-induced cell death. (a) HN31 cells 
were infected with lentivirus-encoding short-hairpin RNA (shRNA) for non-targeting sh-control 
(shC), BAX, or BAK to establish stable knockdown cells. Cells were then infected with 
lentivirus-encoding Flag-tagged Noxa cDNA and an empty vector as a control. Equal amounts of 
total lysates were subjected to Western blot analysis with the indicated antibodies. (b) HN31 
shBAX cells were transiently infected with lentivirus-encoding shRNA for non-targeting control 
or BAK. Cells were then infected with lentivirus-encoding Flag-tagged Noxa cDNA or an empty 
vector as a control. Equal amounts of total lysates were subjected to Western blot analysis using 
indicated antibodies. GAPDH was used as a loading control for both Western blots. [-: control, 







5.8 Noxa expression not induced in cisplatin-resistant isogenic cell lines 
  Knowing that prolonged exposure to cisplatin often results in acquired resistance in 
tumor, we set out to establish cisplatin resistant cell lines so that we may analyze the 
mechanisms that led to resistance. We treated HNSCC cell lines with low doses of cisplatin for a 
prolonged period of time, and monitored their increase in resistance by performing WST-1 
assays after treatment. We were able to establish a isogenic cisplatin-resistant cell line from 
HN31 cells. HN31 and HN31R cell lines were seeded in 6 well plates and treated with their IC50 
cisplatin concentrations (20 µM for HN31). Cells were harvested at 0, 8, 16, and 24 hour after 
the treatment and total lysates were equally loaded into Western blots to examine the differences 
in protein expressions between the parental and resistant cell line (Figure 13a). In HN31R cells, 
we observed a reduction of cleaved-PARP compared to the parental cell line (HN31). This data 
indicates that the acquired resistant cells are undergoing less apoptosis than their isogenic 
parental counterparts. Furthermore, the resistant cells both showed less induction of pro-
apoptotic protein Noxa, which may be attributing to this decrease in apoptosis within those cells. 
Observing this, we decided to investigate whether Noxa overexpression in these resistant cells 
would be capable of inducing cell death. To examine this we infected the HN31R cell line with 
lentivirus-encoding Flag-tagged Noxa cDNA or an empty vector as a control. Equal amounts of 
the total lysates were subjected to Western blot analysis to detect the changes in protein 
expression levels between the HN31 parental cell and the HN31R cell (Figure 13b). Following 
Noxa overexpression we observed no significant induction of cleaved-PARP to indicate 
increased cell death. We also examined the expression levels of other BCL-2 family proteins and 
noticed that nearly all of them were either more or less expressed when compared to the parental 








Figure 13: HN31R resistant cell line shows little response to cisplatin or Noxa 
overexpression. (a) HN31 and HN31R cells were seeded and treated with 20 µM of cisplatin 
and then harvested following 0, 8, 16, and 24 hours of exposure. Equal amounts of the total 
lysates were subjected to Western blot analysis with the indicated antibodies. (b) HN31 and 
HN31R cells were infected with lentivirus-encoding Flag-tagged Noxa cDNA or an empty vector 
as a control. The infected cells were harvested after 24 hours of incubation. Equal amounts of the 
total lysates were subjected to Western blot analysis with the indicated antibodies. GAPDH was 









  Cisplatin treatment of HNSCC results in DNA damage, which then induces p53 to 
prevent further DNA replication or induce apoptosis if DNA is unable to be prepared. When 
determining IC50 of the HNSCC cell lines tested, we observed that the IC50 of p53 wild-type cell 
lines  (HN30 and UMSCC1) tended to possess a higher sensitivity to cisplatin than that of p53 
deleted and non-functional p53 cell lines (Table 1 and Figure 6). This data suggest that activation 
of the p53-dependent pathway could sensitize the cells to cisplatin treatment compared in the p53 
deleted or non-functional cell lines.  
  The BCL-2 family members are the primary guardians of mitochondria-dependent 
apoptosis. Cisplatin, a chemotherapeutic drug, has been shown to induce cell death through 
mechanisms other than apoptosis [45,46]; however, our results indicate that the cisplatin-triggered 
cell death is mainly through BCL-2 family-dependent mitochondrial apoptosis. Of these BCL-2 
family proteins, Noxa is up-regulated during cisplatin treatment in HNSCC cell lines. When 
treating HN31 shNoxa cells with cisplatin, we observed a decrease in cleaved-PARP when 
compared to the control cells (Figure 7). This data confirms that Noxa is important for cisplatin-
induced cell death in HNSCC cell lines. Similar to HNSCC, Noxa has also been shown to be up-
regulated during cisplatin-induced cell death in breast and cervical cancer cell lines [44]. Perhaps 
there are even more types of cancer in which Noxa plays a critical role chemotherapeutic-
induced cell death.   
  Our data showed that Noxa overexpression alone is capable of inducing cell death in 
HNSCC cell lines (Figure 8). With Noxa overexpression, the level of cleaved-PARP was 
increased in each cell line regardless of p53 status. Furthermore, we determined that Noxa-
induced cell death is tumor specific by analyzing the immortalized normal oral keratinocytes 
	
	 43	
(NOK). When overexpressing Noxa in NOK, we detected no induction of cleaved-PARP 
compared to that in the control NOK (Figure 9). While the mechanism is not yet known as to 
why Noxa-induced cell death is tumor specific, this data contributes to a potential of using Noxa 
as a therapeutic strategy to treat head and neck cancer. Future research with Noxa overexpression 
in other non-transformed cell lines would certainly provide greater support to our current results.  
  We then examined whether the BH3 domain of Noxa is required to induce cell death in 
HNSCC cells. When transfecting the Noxa 3E mutant Noxa into HN8 and HN31 cells, we 
observed no induction of cleaved-PARP with the 3E mutant compared to the control. These 
results indicate that the BH3 domain of Noxa is essential for Noxa-induced cell death in HNSCC 
cells (Figure 10a). Furthermore, we confirmed that the 3E Noxa mutant is unable to bind to  
MCL-1 to allow the release of BAK and subsequent apoptosis (Figure 10c). Others have also 
shown that few mutations within the BH3 domain of BCL-2 proteins will alter the selectiveness 
of the protein and their ability to induce apoptosis [48]. With this information, we are developing a 
peptide of Noxa BH3 domain to maintain Noxa’s function in inducing apoptosis. This BH3 
peptide would minimize side effects on tumor surrounding tissues by only inhibiting the BCL-2 
pro-survival protein MCL-1. Using the peptide when treating head and neck cancers that rely on 
their development by MCL-1 up-regulation could prove useful. For example, MCL-1 up-
regulation has been identified in in 9% of luminal B breast cancers [56] and 54% of triple negative 
breast cancers after treatment with neoadjuvant chemotherapies [57]. 
  Under survival conditions it is known that MCL-1 and BCL-XL are bound to BAK to 
inhibit apoptosis. These interactions can occur with the BAK BH3 domain, which is also 
required for the BAK oligomerization and induction of mitochondrial-dependent apoptosis [49]. 
Following up-regulation of Noxa, MCL-1 is sequestered to the mitochondria and targeted for 
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degradation, allowing BAK to be displaced to induce apoptosis. When Noxa was overexpressed, 
the interaction of BAK and MCL-1 decreased, which indicates that up-regulation of Noxa results 
in the release of BAK from MCL-1 to induce cell death (Figure 11a). Furthermore, by using a 
conformational specific BAK antibody we were able to confirm that BAK was activated by Noxa 
overexpression, which is critical for BAK dimerization and outer mitochondrial pore formation 
(Figure 11b). Interestingly, we also observed BAX activation when Noxa was overexpressed 
(Figure 11c). With this information we then confirmed that there was no interaction between 
BAX and MCL-1 (Figure 11d). Knowing that MCL-1 and BAX do not interact, we can conclude 
that Noxa is functioning through some independent mechanism of MCL-1 sequestration to 
activate BAX. Still, the mechanism as to how Noxa induces BAX activation is not yet known.  
Other BH3-only proteins may sequester BCL-XL or BCL-2 to induce BAX activation, since 
Noxa is not capable of providing that function [47,48]. Thus, immunoprecipitation with other BCL-
2 family members and their interaction with BAX with and without Noxa overexpression may 
provide explanation for this phenomenon.  
  Knowing that BAX and BAK are activated upon Noxa overexpression, we determined 
whether Noxa is primarily dependent on their activation to induce cell death. When performing 
single knockdowns of BAX and BAK, the levels of cleaved-PARP were reduced partially in both 
cells compared to those in control cells (Figure 12a). Furthermore, we performed double 
knockdowns of BAX and BAK (Figure 12b). Under these conditions we observed no induction 
of cleaved-caspase-3, which suggest that Noxa is primarily inducing cell death through the BAX 
and BAK-dependent pathway. Future research should confirm this data by performing Annexin 
V and propidium iodide staining followed by flow cytometry (FACS analysis) to quantify this 
reduction in cell death observed in our Western blot analyses.  
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  Over a prolonged exposure to chemotherapeutic agents, patients often experience tumor-
acquired resistance. Therefore, we attempted to mimic this situation in vitro by treating HNSCC 
cells with low doses of cisplatin for several weeks. When treating the resistant cells (HN31R) 
with cisplatin, our results show a decrease in cleaved-PARP compared to the parental HN31 cell 
line (Figure 13a). Furthermore, endogenous Noxa expression levels were decreased in HN31R 
cells. When investigating whether Noxa overexpression was capable of recovering cell death in 
HN31R cells, we observed no increase of cleaved-PARP in Noxa overexpressed cells compared 
to that in control cells (Figure 13b). When analyzing the expression of other BCL-2 family 
proteins, we noticed that the expression levels in HN31R cells were altered compared to those in 
the parental HN31 cells. Among the pro-survival proteins, the levels of BCL-XL and MCL-1 
appear reduced, but the level of BCL-2 is greatly increased in HN31R cells. Pro-apoptotic BAK 
exhibits a reduced expression, but BAX expression is increased in the resistant cells. Upon these 
results, it is currently unclear as to what change in machinery is playing a role in acquired 
resistance within this HNSCC cell line. Further research is needed to elucidate the genetic 
mutations in the HN31R cell line. Combination therapies with BCL-2 pro-survival protein 
inhibitors should also be investigated whether there is a recovery of cell death in the resistant cell 
line. In particular, a combination of Noxa overexpression and ABT-263 (BCL-2 and BCL-XL 
inhibitor) may be sufficient to induce cell death in HN31R cells.  
  In summary, our results indicate five important findings. First, Noxa induction is required 
for cisplatin-induced cell death in HNSCC cell lines. Second, Noxa overexpression alone is 
capable of inducing tumor-specific cell death in HNSCC cell lines. Third, the BH3 domain of 
Noxa is required for cell death induction through the inhibition of MCL-1 function. Fourth, 
Noxa-mediated cell death is primarily activated through BAX and BAK. Fifth, the cisplatin-
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resistant isogenic HN31 cell line is not as sensitive to Noxa overexpression as its parental cell 
line. These insights may be useful for the development of novel therapeutic strategy to treat head 
and neck cancer.  
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